2025
Lipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylation
Liu J, Shen Y, Liu J, Xu D, Chang C, Wang J, Zhou J, Haffty B, Zhang L, Bargonetti J, De S, Hu W, Feng Z. Lipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylation. Nature Communications 2025, 16: 1762. PMID: 39971971, PMCID: PMC11839913, DOI: 10.1038/s41467-025-57099-9.Peer-Reviewed Original ResearchConceptsGain-of-functionTumor suppressive function of p53Mutp53 accumulationAccumulate to high levelsFunction of p53Mutant p53 accumulationTumor suppressive functionMutant p53Subcutaneous xenograft tumor modelMutp53Promote tumorigenesisP53 accumulationPalmitoylationPotential therapeutic strategyXenograft tumor modelFASNTumor modelTumor organoidsTransgenic miceTherapeutic strategiesP53
2017
Loss of LZAP inactivates p53 and regulates sensitivity of cells to DNA damage in a p53-dependent manner
Wamsley JJ, Gary C, Biktasova A, Hajek M, Bellinger G, Virk R, Issaeva N, Yarbrough WG. Loss of LZAP inactivates p53 and regulates sensitivity of cells to DNA damage in a p53-dependent manner. Oncogenesis 2017, 6: e314-e314. PMID: 28394357, PMCID: PMC5520489, DOI: 10.1038/oncsis.2017.12.Peer-Reviewed Original ResearchDNA damage-induced cell deathDamage-induced cell deathSide effectsDNA damageDNA damaging treatmentsMutant p53Cell lung cancerSerious side effectsWild-type p53 cellsP53-dependent mannerCommon cancer therapiesMajority of cancersCell fateProtein bindsSensitivity of cellsLung cancerP53 regulatorsCellular DNACell deathDamage DNAMutation statusHuman cancersDamaging treatmentsAnticancer effectsType p53
2014
Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A
Gupta R, Dong Y, Solomon PD, Wettersten HI, Cheng CJ, Min JN, Henson J, Dogra SK, Hwang SH, Hammock BD, Zhu LJ, Reddel RR, Saltzman WM, Weiss RH, Chang S, Green MR, Wajapeyee N. Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A. Proceedings Of The National Academy Of Sciences Of The United States Of America 2014, 111: e3062-e3071. PMID: 25024194, PMCID: PMC4121806, DOI: 10.1073/pnas.1411370111.Peer-Reviewed Original ResearchConceptsP53-mediated transcriptional activationCyclin-dependent kinase inhibitor 1AMutant p53Telomerase inhibitionTumor suppressor p53Transcriptional activationSynergistic tumor suppressionTelomere dysfunctionCheckpoint proteinsP53 upregulated modulatorTumor suppressionCDK inhibitorsSuppressor p53Inhibitor 1AP53 activityTelomeraseHuman cancersCancer cell linesApoptosis inductionPharmacological inhibitionApoptosisCell linesPharmacological restorationP21Growth inhibition
2009
Strategies to Circumvent Resistance to Apoptosis in Prostate Cancer Cells by Targeted Necrosis
Dinnen R, Petrylak D, Fine R. Strategies to Circumvent Resistance to Apoptosis in Prostate Cancer Cells by Targeted Necrosis. 2009, 327-346. DOI: 10.1007/978-1-4020-9597-9_14.Peer-Reviewed Original ResearchProstate cancer cellsCancer cellsCircumvent resistanceCancer linesHuman prostate cancer cellsProstate cancer cell linesMutant p53Prostate cancer linesNormal cellsCancer cell linesMechanism of cytotoxicityChemotherapy resistanceNecrosisDrug resistanceReactive oxygen speciesHigh levelsSelective killingApoptosisCell linesIntracellular generationNecrotic pathwaysP53Cell deathDeath pathwaysOxygen species
2008
Telomere dysfunction and tumour suppression: the senescence connection
Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nature Reviews Cancer 2008, 8: 450-458. PMID: 18500246, PMCID: PMC3688269, DOI: 10.1038/nrc2393.Peer-Reviewed Original ResearchConceptsTelomere dysfunctionDysfunctional telomeresDNA damage responseKey PointsTelomeresEukaryotic chromosomesGenome instabilityShelterin complexApoptotic programDamage responseRepetitive sequencesCellular senescenceTelomeric endTumor suppressionProtein resultsP53 pathwayMutant p53TelomeresSpontaneous tumorigenesisSenescenceTumorigenesisMouse modelChromosomesDysfunctionProteinApoptosis
1997
Re: Relationship Between Lifetime Ovulatory Cycles and Overexpression of Mutant p53 in Epithelial Ovarian Cancer
Risch H. Re: Relationship Between Lifetime Ovulatory Cycles and Overexpression of Mutant p53 in Epithelial Ovarian Cancer. Journal Of The National Cancer Institute 1997, 89: 1726-1727. PMID: 9390546, DOI: 10.1093/jnci/89.22.1726-a.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply